Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study

Oncology Letters

Volumn 7, Issue 1, 2014, Pages 125-130

  Li, Yun Fei ^a,b,c   Wang, Qin Zhang ^b   Zhang, Tao Tao ^b,c   Li, Lei ^a   Wang, Jiang Ping ^b   Ding, Guo Fu ^b   He, Da Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b SHIHEZI UNIVERSITY   (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Castration resistant prostate cancer; Docetaxel; Interferon 2b

Indexed keywords

ALPHA2B INTERFERON; DOCETAXEL; PREDNISOLONE;

ADULT; AGED; ANEMIA; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PILOT STUDY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY;

EID: 84888395669     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1653     Document Type: Article

References (28)

1. Feldman BJ and Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45, 2001.
2. Pienta KJ and Bradley D: Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12: 1665-1671, 2006.
3. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004.
4. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242-245, 2008.
5. Makarovskiy AN, Siryaporn E, Hixson DC and Akerley W: Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59: 1198-1211, 2002.
6. McDonnell TJ, Troncoso P, Brisbay SM, et al: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944, 1992.
7. Banerjee PP, Banerjee S and Brown TR: Bcl-2 protein expression correlates with cell survival and androgen independence in rat prostatic lobes. Endocrinology 143: 1825-1832, 2002.
8. Ventura A, Kirsch DG, McLaughlin ME, et al: Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661-665, 2007.
9. Leprince D, Crepieux P, Laudet V, Flourens A and Stehelin D: A new mechanism of oncogenic activation: E26 retroviral v-ets oncogene has inverted the C-terminal end of the transcription factor c-ets-1. Virology 194: 855-857, 1993.
10. Liu C, Zhu Y, Lou W, et al: Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 73: 418-427, 2013.
11. Panaretakis T, Pokrovskaja K, Shoshan MC and Grander D: Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene 22: 4543-4556, 2003.
12. Davol PA, Goulette FA, Frackelton AR Jr and Darnowski JW: Modulation of p53 expression by human recombinant interferon-alpha2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res 56: 2522-2526, 1996.
13. Huang SF, Kim SJ, Lee AT, et al: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res 62: 5720-5726, 2002.
14. Emerson L and Morales A: Intralesional recombinant alpha-interferon for localized prostate cancer: a pilot study with follow-up of >10 years. BJU Int 104: 1068-1070, 2009.
15. Shinohara N, Abe T, Sazawa A, et al: Interferon-α-based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ. Jpn J Clin Oncol 42: 113-119, 2012.
16. Mocellin S, Pasquali S, Rossi CR and Nitti D: Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 102: 493-501, 2010.
17. van Haelst-Pisani CM, Richardson RL, Su J, et al: A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer 70: 2310-2312, 1992.
18. Bulbul MA, Huben RP and Murphy GP: Interferon-beta treatment of metastatic prostate cancer. J Surg Oncol 33: 231-233, 1986.
19. Padhani AR and Ollivier L: The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986, 2001.
20. DiPaola RS, Chen YH, Stein M, et al: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med 8: 20, 2010.
21. Anatol P, Danuta P, Janusz D and Bozena P: Expression of bcl-2 protein in chronic hepatitis C: effect of interferon alpha 2b with ribavirin therapy. World J Gastroenterol 11: 2949-2952, 2005.
22. Amato RJ and Mohammad T: Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer. J Exp Ther Oncol 7: 41-47, 2008.
23. Rosevear HM, Lightfoot AJ, Nepple KG and O'Donnell MA: Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α. J Urol 185: 67-71, 2011.
24. Panasiuk A, Prokopowicz D and Dzieciol J: p53 protein expression in chronic hepatitis C; effect of interferon alpha 2b therapy. Hepatogastroenterology 52: 1176-1179, 2005.
25. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30: 1534-1540, 2012.
26. Koirala J, Gandotra SD, Rao S, et al: Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepat 14: 782-787, 2007.
27. Chang AY, Fisher HA, Spiers AS and Boros L: Toxicities of human recombinant interferon-alpha 2 in patients with advanced prostate carcinoma. J Interferon Res 6: 713-715, 1986.
28. ten Tije AJ, Verweij J, Carducci MA, et al: Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23: 1070-1077, 2005.